Xi’an-based med-tech firm TianLong Science and Technology Co., Ltd has reportedly entered into a supply agreement with hospitals in northern Thailand to provide molecular diagnostic products for the detection of hepatitis B and C viruses (HBV/HCV). The company has secured a 7-year supply agreement, which was reached in October 2022.
TianLong’s Diagnostic Solutions for Hepatitis B and C
TianLong’s HCV and HBV reagents are utilized in conjunction with its nucleic acid extractor, PANA9600S, and PCR system, Gentier 96, to offer rapid and precise testing capabilities. These products enable efficient diagnosis of hepatitis infections, which is crucial for patient care and disease management.
Expansion Plans Following Successful Launch
Following the successful launch in northern Thailand, TianLong is exploring opportunities to broaden its reach by partnering with additional hospitals for HBV/HCV testing. The company is also considering expanding its product offerings to include diagnostics for sexually transmitted infections (STIs) in the future, demonstrating its commitment to enhancing public health through advanced diagnostic solutions.-Fineline Info & Tech
